Endoscopic thermal vapor ablation in patients with homogenous lung emphysema-a pilot study

Thoraxklinik Universitätsklinikum Heidelberg0 个研究点目标入组 10 人开始时间: 2016年11月23日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Serious pulmonary emphysema:
•FEV1 <45%, RV> 150%, TLC> 100%, maximum drug therapy according to GOLD
•blood gases:
•PO2> 45 mmHg at room air at rest; PCO2 <55 mmHg with room air at rest
•-Homogeneity:
•Homogenous pulmonary emphysema, which was already detected prior to study inclusion by a thoracic HCRT and a perfusion scintigraphy; Confirmation of homogeneity by computer-assisted emphysem quantification (YACTA®)
•-patient age:> 30 years
•-Stable COPD:
•No exacerbation in the last 8 weeks; Cortisone dose <20 mg prednisolone equivalent
•-Not- or ex-smoker:
•Nicotine abstinence> 4 months; Current CoHb <2.5%
•-Patient informed consent:
•Signed patient information for an endoscopic LVR; Willingness to participate in the control investigations according to the protocol

•-Nutritional status:
•BMI <18 mg / kg²
•Significant bronchiectasis:
•Sputum quantity> 4 tablespoons /day
•-physical resilience:
•Walking distance <140 m
•- Difficult cardiac disease:
•Z. n. Myocardial infarction in the last 6 weeks; Decompensated heart failure; Cardio-myopathy with medium to highly limited LVF; Long term medication with Clopidogrel
•-Pre-operations:
•Z.n. Lung resection (LVRS / lobectomy / pneumonectomy)
•-Pregnancy:
•Existing pregnancy; Female subject of childbearing age without adequate contraception

发起方

Thoraxklinik Universitätsklinikum Heidelberg